Anti-inflammatory therapeutics for the treatment of atherosclerosis. - Wikidata - wikimedia - TriplyDB

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

http://www.wikidata.org/entity/Q37626768

about

Kruppel-like factor 15 is critical for vascular inflammation Anti-Inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis The outliers become a stampede as immunometabolism reaches a tipping point Glucose metabolic trapping in mouse arteries: nonradioactive assay of atherosclerotic plaque inflammation applicable to drug discovery Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.Perspectives and opportunities for nanomedicine in the management of atherosclerosis.Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages.CD40L and Its Receptors in Atherothrombosis-An Update The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis Lysophosphatidic acid in atherosclerotic diseases Establishment of an interleukin-1β-induced inflammation-activated endothelial cell-smooth muscle cell-mononuclear cell co-culture model and evaluation of the anti-inflammatory effects of tanshinone IIA on atherosclerosis.Scan-rescan reproducibility of quantitative assessment of inflammatory carotid atherosclerotic plaque using dynamic contrast-enhanced 3T CMR in a multi-center study.An agent-based model of the response to angioplasty and bare-metal stent deployment in an atherosclerotic blood vessel.The role of uridine adenosine tetraphosphate in the vascular system.Dihydroaustrasulfone Alcohol (WA-25) Impedes Macrophage Foam Cell Formation by Regulating the Transforming Growth Factor-β1 Pathway.EETs Attenuate Ox-LDL-Induced LTB4 Production and Activity by Inhibiting p38 MAPK Phosphorylation and 5-LO/BLT1 Receptor Expression in Rat Pulmonary Arterial Endothelial Cells.Mechanisms of thrombosis in obesity.Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway.Alopecia Areata Increases the Risk of Stroke: a 3-year Follow-Up Study.HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.Highly Selective Photothermal Therapy by a Phenoxylated-Dextran-Functionalized Smart Carbon Nanotube Platform.Anti-inflammatory effect and action mechanisms of traditional herbal formula Gamisoyo-san in RAW 264.7 macrophages.Folate receptor: a macrophage "achilles' heel"?Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions Digoxin reduces atherosclerosis in apolipoprotein E-deficient mice Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases.Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK Ginseng extracts restore high-glucose induced vascular dysfunctions by altering triglyceride metabolism and downregulation of atherosclerosis-related genes.Chemokines: established and novel targets in atherosclerosis.Regulation of the inflammatory response of vascular endothelial cells by EPAC1.Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.The effects of extracellular matrix proteins on neutrophil-endothelial interaction--a roadway to multiple therapeutic opportunities.Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).Emerging anti-inflammatory drugs for atherosclerosis.Biased agonism at chemokine receptors: obstacles or opportunities for drug discovery?Integrin activation as an alternative treatment approach for inflammatory diseases.Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits.

P2860

Q24321728-8528DC3D-32EC-4784-81D6-49B27DD0F668 Q26825251-BEBCA605-5773-48D9-B165-EAE673DB59C2 Q27005951-58F08F48-33D6-4E9B-B944-24CD81A7DF66 Q28485353-78AB1100-CAE2-4C5D-84CC-03A01F17E713 Q30357131-3C1A8868-2D8F-49AA-921D-F545474871C4 Q30455490-10451BF6-6F19-430E-AE8B-3EB37BBE5480 Q33613358-D81F1207-63EE-49EE-8684-1B491549F074 Q33814059-188F7C00-8B5B-4048-9B74-C98DDA9478D3 Q33838927-5E8D09AD-DFF2-4D4A-A2B6-74351405B873 Q34273486-EA6C2097-1E17-4D6E-BB98-B0806B37F5DE Q34474800-9A5E5D77-EECD-450C-B597-E908B4E5D936 Q34544570-13644313-B20F-41FA-B076-77D9EE5F0654 Q35147533-E622DA49-E9B9-4FFB-A5D5-6F2820FE3DED Q35504071-59C48435-840D-47A1-B82D-191DDA47F819 Q35626888-2C311FBE-E507-4CBD-9D27-6555760A7E1D Q35649907-0FF4D7B5-8594-431A-B432-8D782A66C14F Q35653311-3AF49C9F-5A8E-4272-95C3-15F1EBD72010 Q35691449-D369BB7B-5DEF-4C13-AEBA-7CC4CA498ADF Q35785185-A5C655FC-E6F8-439A-9C1F-767180AFD0C6 Q35795262-A74B633B-E452-4236-BF25-15EFFC526B93 Q35914754-C7C8366F-6912-43E9-872E-DE4FDA388EDB Q35974471-38F7A30D-D3E3-47DF-BD4F-A575F5FAD8C2 Q36079200-7E04698B-E5AE-4C4A-BF7A-99B8088B36DA Q36366267-5D000FEB-9976-41A2-BAB7-498F1A1DF327 Q36728741-6D39BBC5-064E-4A2F-96FB-DE089B4F0518 Q36746012-93F6E6C6-401B-4195-8924-83E8BC4E5D65 Q36797363-6F4C7871-EC07-4DA4-B847-05142C66BBC6 Q36817578-FF961456-5D49-4263-A6DB-4580145B0860 Q36848196-AB857639-210F-4134-BC58-755C786F14C2 Q37002637-341689E4-95B5-4B97-9AEA-050A16CB0FA2 Q37249857-020AF886-E6C2-45B8-AABD-45C7BB366105 Q37950973-82EDC8E2-D5F6-4228-8ACA-DDB3FF7D67EF Q37965220-3E601D7A-FEFD-4581-B3D9-D3A29B6F030F Q37991749-E32BF56E-F6CB-4E6E-9CEA-DE8E65A4FDF2 Q38021995-65BE2463-8C3F-432F-9B00-051E1D29335A Q38072094-9FEE0F8A-5B39-4F95-88BC-9348E34ACB71 Q38106998-5812FE08-B451-4421-B3AB-A18A80604C08 Q38678404-C40F522B-FA4B-435D-8935-F4395EB7DE01 Q39018123-FAA94D60-F294-48E8-89A7-479489C06951 Q39040956-F9324492-7B8E-4410-AB7F-DA25A6F9B2FD

P2860

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

http://www.wikidata.org/entity/Q37626768

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

@en

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

@nl

type

label

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

@en

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

@nl

prefLabel

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

@en

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

@nl

P1433

Q37626768-2BCF1E3B-B56A-48E6-B584-7DDE67D0471F

P1476

Q37626768-230D9B7C-37F6-4427-8E95-90E2C6CB4CBA

P2093

Q37626768-320D1AE4-5ABF-4C4B-9AE7-4CEC8C0288C7

Q37626768-32DAE834-5755-4324-BCD5-572F5DAD7607

P2860

Q37626768-05897EF3-8929-489C-9582-FBE9A07D5A9C

Q37626768-06616D4A-12AF-49F3-8F7F-1D068309E62B

Q37626768-0B50D341-DDFE-457F-8FD5-008069F6A2BB

Q37626768-0BDEAE54-D0B8-420C-8B24-518A99DD6093

Q37626768-0F692BA4-F3BA-445D-A0ED-155DC1A89385

Q37626768-0F90148E-86EB-4365-A85E-E0DB6A48F60B

Q37626768-0FA28533-3FA8-4E80-ADE5-A384F5292CD4

Q37626768-118ED574-D2E2-4222-A341-29347B5EC102

Q37626768-15B80A06-2523-46A7-A83A-ECF8F8131588

Q37626768-18759896-48FC-444B-B357-CC3CA0EB2C36

P2888

Q37626768-972A4B11-31C3-4065-A84F-9CB7EAA8CB0F

P304

Q37626768-7F31AA3A-F824-451C-BA9C-F63C01EAFC2F

P31

Q37626768-79E99910-1B86-453F-B0A0-CE780BD64E5D

P356

Q37626768-34198421-AF94-4EC0-99AD-BF66E3EDA985

P433

Q37626768-70F68C3B-5381-4B90-9A21-049FD7B1F83A

P478

Q37626768-B83DBB8A-F6BA-4383-AD7B-F64CB83DF261

P577

Q37626768-FF261AAB-1F29-41F8-8A7C-4AF741981991

P698

Q37626768-AF0F9133-B498-4933-A26A-629F145EA521

P921

Q37626768-02AD5763-F577-4E13-ABDF-FA556E5EBC0C

Q37626768-4B00E534-DE54-49B2-AF9B-9F9F95A99705

P932

Q37626768-3C73EDF8-D4DB-410D-929A-A67BF0B44087

P356

P1433

Nature Reviews Drug Discovery

P1476

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

@en

P2093

Israel F Charo

http://www.w3.org/2001/XMLSchema#string

Rebecca Taub

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

Atherosclerosis

Atherosclerosis — An Inflammatory Disease

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis

Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity

Simvastatin with or without ezetimibe in familial hypercholesterolemia

Inflammation in atherosclerosis

P2888

P304

365-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD3444

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21532566

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3947588

http://www.w3.org/2001/XMLSchema#string